Serpentine transmembrane antigens expressed in human cancers...

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07727533

ABSTRACT:
Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SixTransmembraneEpithelialAntigen of theProstate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

REFERENCES:
patent: 6329503 (2001-12-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0146692 (2002-10-01), Yamazaki et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar et al.
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 2003/0100540 (2003-05-01), Zhang et al.
patent: 0 834 563 (1998-04-01), None
patent: 0834563 (1998-04-01), None
patent: 1308459 (2003-05-01), None
patent: 11164691 (1999-06-01), None
patent: 11164691 (1999-06-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO9514772 (1995-06-01), None
patent: WO9514772 (1995-06-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/53071 (1998-11-01), None
patent: WO9853071 (1998-11-01), None
patent: WO9853071 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/61469 (1999-02-01), None
patent: WO9906546 (1999-02-01), None
patent: WO9906548 (1999-02-01), None
patent: WO9906548 (1999-02-01), None
patent: WO9906550 (1999-02-01), None
patent: WO9906550 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO9962941 (1999-12-01), None
patent: WO9962941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO0004149 (2000-01-01), None
patent: WO0004149 (2000-01-01), None
patent: WO0004149 (2000-01-01), None
patent: WO 00/35937 (2000-02-01), None
patent: WO 00/35937 (2000-06-01), None
patent: WO0035937 (2000-06-01), None
patent: WO 00/77021 (2000-12-01), None
patent: WO0077021 (2000-12-01), None
patent: WO0077021 (2000-12-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO0112662 (2001-02-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO0125272 (2001-04-01), None
patent: WO0125272 (2001-04-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO0134802 (2001-05-01), None
patent: WO0134802 (2001-05-01), None
patent: WO 01/40276 (2001-06-01), None
patent: WO0140276 (2001-06-01), None
patent: WO0140276 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO0151633 (2001-07-01), None
patent: WO0151633 (2001-07-01), None
patent: WO 01/57190 (2001-08-01), None
patent: WO 01/57273 (2001-08-01), None
patent: WO 01/57276 (2001-08-01), None
patent: WO 01/57277 (2001-08-01), None
patent: WO 01/60860 (2001-08-01), None
patent: WO0157190 (2001-08-01), None
patent: WO0157190 (2001-08-01), None
patent: WO0157273 (2001-08-01), None
patent: WO0157276 (2001-08-01), None
patent: WO0157276 (2001-08-01), None
patent: WO0157277 (2001-08-01), None
patent: WO0157277 (2001-08-01), None
patent: WO0160860 (2001-08-01), None
patent: WO0160860 (2001-08-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO0170979 (2001-09-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO 01/73032 (2001-10-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO0172962 (2001-10-01), None
patent: WO0173032 (2001-10-01), None
patent: WO0173032 (2001-10-01), None
patent: WO0175067 (2001-10-01), None
patent: WO0175067 (2001-10-01), None
patent: WO 01/86003 (2001-11-01), None
patent: WO0186003 (2001-11-01), None
patent: WO0186003 (2001-11-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 01/96388 (2001-12-01), None
patent: WO0194629 (2001-12-01), None
patent: WO0194629 (2001-12-01), None
patent: WO0196388 (2001-12-01), None
patent: WO 02/10449 (2002-02-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO0210449 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO0230268 (2002-04-01), None
patent: WO0230268 (2002-04-01), None
patent: WO 02/57303 (2002-07-01), None
patent: WO0257303 (2002-07-01), None
patent: WO02057303 (2002-07-01), None
patent: WO 02/59260 (2002-08-01), None
patent: WO0259260 (2002-08-01), None
patent: WO02059260 (2002-08-01), None
patent: WO 02/077013 (2002-10-01), None
patent: WO 02/077186 (2002-10-01), None
patent: WO02077013 (2002-10-01), None
patent: WO02077186 (2002-10-01), None
patent: WO 02/089747 (2002-11-01), None
patent: WO 02/092787 (2002-11-01), None
patent: WO 02/095010 (2002-11-01), None
patent: WO0295010 (2002-11-01), None
patent: WO02089747 (2002-11-01), None
patent: WO02092787 (2002-11-01), None
patent: WO02095010 (2002-11-01), None
patent: WO 02/102993 (2002-12-01), None
patent: WO 02/102994 (2002-12-01), None
patent: WO02102993 (2002-12-01), None
patent: WO02102994 (2002-12-01), None
patent: WO 03/004622 (2003-01-01), None
patent: WO 03/004623 (2003-01-01), None
patent: WO03004622 (2003-01-01), None
patent: WO03004623 (2003-01-01), None
patent: WO 03/009814 (2003-02-01), None
patent: WO03009814 (2003-02-01), None
patent: WO 03/022995 (2003-03-01), None
patent: WO03022995 (2003-03-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 2006/034488 (2006-03-01), None
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Shantz and Pegg (Int J of Biochem and Cell Biol., 1999, vol. 31, pp. 107-122).
McClean and Hill (Eur J of Cancer, 1993, vol. 29A, pp. 2243-2248).
Bowie et al. (1990, Science 247:1306-1310, 1990, p. 1306, col. 2).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
White et al. (Ann. Rev. Med., 2001, 52:125-145).
Gura (1997, Science 278:1041-1042).
Boon (Adv Can Res, 1992, 58:177-210).
Kirkin et al, (1998, APMIS 106:665-679).
Voet et al, (1990) Biochemistry, pp. 1095-1099.
Abu-Threideh et al., Jun. 1998, EMBL/GENBANK/DDBJ Databases.
Abu-Threideh et al., GENBANK, (Accession No. 095034), National Library of Medicine, Bethesda MD, May 1, 1999.
Alberts et al., Molecular Biology of the Cell, 3rd edition (1994) p. 465.
Bellone et al., Immunology Today (1999) 20(10):457-462.
Bowie et al. (1990) Science 247:1306-1310.
Burgess et al. (1990) Jnl. Cell Biol. 111:2129-2138.
Cate et al., GENBANK, (Accession No. W86309), National Library of Medicine, Bethesda MD, Nov. 1998.
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ1121E10), Hinxton, GB.
Database EMBL, “Human BAC clone CTB-167B5 form 7q21, complete sequence,” Jun. 17, 1998 XP002173859 (Accession AC 003991 (Waterstone, R.)).
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Diss et al. (1998) “Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines,” FEBS Letters 427:5-10.
Dulcert et al., GENBANK, (Accession No. Y11840), National Library of Medicine, Bethesda MD, Feb. 11, 1999.
Falk et al., Nature (1991) 351:390-296.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Greenberg et al., PNAS (1995) 92:3439.
Greenspan et al., (Nature Biotechnology 7:936-937 (1999)).
Grimes et al. (1998) “Electrophysiological characterization of voltage-gated Na+current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer,” Journal of Cellular Physiology 175:50-58.
Gura, Science (1997) 278:1041-1042.
Gu

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Serpentine transmembrane antigens expressed in human cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Serpentine transmembrane antigens expressed in human cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serpentine transmembrane antigens expressed in human cancers... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4238973

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.